Search Within

Molecular Imaging and Therapy Service

Formats
  1. Journal Article (1834)
  2. Meeting Abstract (941)
  3. Book Section (179)
  4. Review (161)
  5. Editorial (45)
  6. Conference Paper (40)
  7. Guidelines (32)
  8. Miscellaneous (19)
  9. Correspondence (12)
  10. Research Letter (11)
  11. Book Whole (7)
Groups
  1. Radiology, Department of (3103)
  2. GSK Faculty (1491)
  3. Sloan Kettering Institute Faculty (1250)
  4. Molecular Pharmacology and Chemistry Program Faculty (1235)
  5. Department of Medicine (1003)
  6. Sloan Kettering Institute Postdocs (885)

More Groups

People
  1. Steven Larson (962)
  2. Heiko Schoder (555)
  3. Neeta Pandit-Taskar (348)
  4. John Humm (284)
  5. Hebert Vargas Alvarez (267)
  6. Lisa Bodei (211)

More People

Years
  1. 2025 (75)
  2. 2024 (134)
  3. 2023 (176)
  4. 2022 (176)
  5. 2021 (200)
  6. 2020 (195)

More Years

Publications
  1. Journal of Nuclear Medicine (577)
  2. Journal of Clinical Oncology (251)
  3. European Journal of Nuclear Medicine and Molecular Imaging (130)
  4. Blood (102)
  5. International Journal of Radiation Oncology, Biology, Physics (73)
  6. Clinical Nuclear Medicine (72)

More Publications

Publishers
  1. Society of Nuclear Medicine (577)
  2. Springer (434)
  3. Elsevier Inc. (286)
  4. American Society of Clinical Oncology (263)
  5. Lippincott Williams & Wilkins (155)
  6. American Association for Cancer Research (151)

More Publishers

Results (3281)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The phase 3 NETTER-1 study of [(177)Lu-]Lu-DOTA-TATE in patients with midgut neuroendocrine tumours: Final overall survival and long-term renal safety
    Meeting Abstract

    Kunz, P.; Caplin, M. E.; Ruszniewski, P. B.; Bodei, L.; Hendifar, A.; Mittra, E.; Wolin, E. M.; Yao, J. C.; Pavel, M. E.; Grande, E.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2021)

    Fulltext@MSK | Save
  • 18F-fluoroglutamine PET as a promising prognostic tool in IDH mutant glioma
    Meeting Abstract

    Krebs, S.; Graham, M. S.; Grkovski, M.; Mauguen, A.; Goel, R.; Thakur, S. B.; Schaff, L. R.; Mellinghoff, I. K.; Young, R. J.; Kaley, T.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2021)

    Fulltext@MSK | Save
  • The imaging performance of 89Zr in TOF PET/CT system
    Meeting Abstract

    Parlak, Y.; Goksoy, D.; Sezgin, C.; Medine, I.; Gumuser, G.; Aras, O.; Sayit, E.
    European Journal of Nuclear Medicine and Molecular Imaging (2021)

    Fulltext@MSK | Save
  • Precision radiotherapy: Reduction in radiation for oropharyngeal cancer in the 30 ROC trial
    Journal Article

    Riaz, N.; Sherman, E.; Pei, X.; Schöder, H.; Grkovski, M.; Paudyal, R.; Katabi, N.; Selenica, P.; Yamaguchi, T. N.; Ma, D.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Dosimetry in clinical radiopharmaceutical therapy of cancer: Practicality versus perfection in current practice
    Review

    Pandit-Taskar, N.; Iravani, A.; Lee, D.; Jacene, H.; Pryma, D.; Hope, T.; Saboury, B.; Capala, J.; Wahl, R. L.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Tumor response to radiopharmaceutical therapies: The knowns and the unknowns
    Review

    Sgouros, G.; Dewaraja, Y. K.; Escorcia, F.; Graves, S. A.; Hope, T. A.; Iravani, A.; Pandit-Taskar, N.; Saboury, B.; James, S. S.; Zanzonico, P. B.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Low incidence rates of mucositis, febrile neutropenia or sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia with targeted delivery of anti-CD45 iodine ((131)I) apamistamab [Iomab-B]
    Meeting Abstract

    Natwa, M.; Passalaqua, S.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Mhlanga, J.; Wahl, R.; Avril, N.; more...
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Relationship of marrow radiation dose and timing of engraftment for targeted radioimmunotherapy with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] in patients with active relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Passalaqua, S.; Natwa, M.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Mhlanga, J.; Wahl, R.; Avril, N.; more...
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Blood based genomic assessment of the clinical efficacy and toxicity of peptide receptor radionuclide therapy (PRRT)
    Meeting Abstract

    Bodei, L.; Raj, N.; Do, R. K. G.; Krebs, S.; Reidy, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schoder, H.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save